On September 21, 2017 –(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York. Thomas Lynch, chief scientific officer, will answer questions about the company at 11:00 a.m. EDT (Press release, Bristol-Myers Squibb, SEP 21, 2017, View Source [SID1234520581]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.